Sangamo Therapeutics rises on FDA feedback for gene therapy study
22/10/2024 13:34
** Shares of genomic medicine company Sangamo Therapeutics
SGMO.O rise 6% to 96 cents premarket
** Co says the U.S. FDA has agreed that data from ongoing
early-mid-stage study can serve as the primary basis for
accelerated approval of its experimental gene therapy to treat
Fabry disease
** Fabry disease is an inherited disorder caused by the
buildup of a type of fat in the body's cells
** No additional registrational study is required to support
accelerated approval for the gene therapy, isaralgagene
civaparvovec - SGMO
** SGMO says complete dataset from the study will be
available in H1 2025 with a filing expected in H2 2025
** Up to last close, stock was up 68% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))